Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Peter D. R. Higgins
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Elevated Fecal Calprotectin Associates With Adverse Outcomes fromClostridium Difficileinfection in Older Adults
Infectious Diseases
Medicine
Infectious Diseases
Immunology
Microbiology
Microbiology
Related publications
Erratum To: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results From an Open-Label, 48-Week Extension Study
Clinical Drug Investigation
Medicine
Pharmacology
Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study
Journal of the American Academy of Dermatology
Dermatology
Pd50-06 Long-Term Safety and Tolerability of Oral Testosterone (Lpcn 1021) in Hypogonadal Men: Results From the 52-Week Phase 3 Study
Journal of Urology
Urology
Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study
Arthritis Research & Therapy
Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials
The Lancet Haematology
Hematology
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
Journal of the American Academy of Dermatology
Dermatology
SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study
Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
